Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk

Diabetologia
P J BingleyEuropean Nicotinamide Diabetes Intervention Trial (ENDIT) Group

Abstract

To examine the role of additional immune, genetic and metabolic risk markers in determining risk of diabetes in islet cell antibody (ICA)-positive individuals with a family history of type 1 diabetes recruited into the European Nicotinamide Diabetes Intervention Trial. Five hundred and forty-nine first-degree relatives with confirmed ICA levels > or =20 Juvenile Diabetes Foundation units (mean age 15.9 years; interquartile range 10.4-33.7 years) were recruited from 20 countries. OGTTs and IVGTTs were performed at baseline, antibodies to glutamate decarboxylase (GADA), protein tyrosine phosphatase (IA-2A) and insulin (IAA) were determined by RIA, and HLA class II genotyping was performed by PCR of sequence-specific oligonucleotides. One hundred and fifty-nine participants developed diabetes within 5 years. Univariate analysis showed that the cumulative risk of development of diabetes within 5 years varied according to age, relationship to the proband, positivity for IAA, IA-2A and GADA, number and combination of islet antibodies, HLA class II genotype, baseline glucose tolerance, and first-phase insulin secretion, but not gender or incidence of childhood type 1 diabetes in the background population. Children aged < or =10 years ...Continue Reading

Associated Clinical Trials

References

Oct 1, 1992·Diabetes Care·P J BingleyE A Gale
Jan 1, 1995·Annual Review of Immunology·L S WickerL B Peterson
Jul 31, 2001·Lancet·M A Atkinson, G S Eisenbarth
Nov 29, 2001·Diabetologia·A GreenUNKNOWN EURODIAB TIGER Study Group. Europe and Diabetes
Apr 6, 2002·Diabetologia·A J K WilliamsUNKNOWN ENDIT Screening Group. European Nicotinamide Diabetes Intervention Trial
May 31, 2002·The New England Journal of Medicine·UNKNOWN Diabetes Prevention Trial--Type 1 Diabetes Study Group
Dec 19, 2002·Diabetologia·K DecochezUNKNOWN Belgian Diabetes Registry
Apr 11, 2003·Diabetologia·UNKNOWN European Nicotinamide Diabetes Intervention Trial Group
Mar 20, 2004·Clinical and Experimental Immunology·S HoppuUNKNOWN Childhood Diabetes in Finland Study Group
Mar 27, 2004·Lancet·E A M GaleUNKNOWN European Nicotinamide Diabetes Intervention Trial (ENDIT) Group
Aug 18, 2004·The Journal of Clinical Investigation·Peter AchenbachEzio Bonifacio
Oct 14, 2004·Diabetologia·S FourlanosL C Harrison
Dec 2, 2004·Journal of Autoimmunity·Sanna HoppuUNKNOWN Childhood Diabetes in Finland Study Group
May 21, 2005·Annals of Medicine·Anita KondrashovaHeikki Hyöty
Jun 29, 2005·Diabetes Care·Jay S SkylerUNKNOWN Inhaled Insulin Phase III Type 1 Diabetes Study Group

❮ Previous
Next ❯

Citations

Jan 15, 2008·Diabetologia·P AchenbachUNKNOWN ENDIT Group
May 1, 2008·Nature Clinical Practice. Endocrinology & Metabolism·Jennifer SherrKevan C Herold
Jul 21, 2007·Nature Reviews. Immunology·Lucienne Chatenoud, Jeffrey A Bluestone
Aug 2, 2013·International Journal of Biological Sciences·Yan-Ling WuWen Zhang
Feb 23, 2010·Nature Reviews. Endocrinology·Lucienne Chatenoud
May 23, 2015·Diabetes Care·Ezio Bonifacio
Nov 28, 2012·La Presse médicale·Christian Boitard
Jun 19, 2012·The Medical Clinics of North America·Smita Gupta
Aug 21, 2010·Endocrinology and Metabolism Clinics of North America·Ezio Bonifacio, Anette G Ziegler
Oct 1, 2008·Pediatric Diabetes·Jeffrey L MahonUNKNOWN Type 1 Diabetes TrialNet Study Group
Jul 11, 2008·Diabetes/metabolism Research and Reviews·R D G LeslieP Pozzilli
May 25, 2007·Clinical and Experimental Immunology·I TruyenUNKNOWN Belgian Diabetes Registry
Aug 5, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·J A ToddC Mathieu
Nov 16, 2010·Journal of Diabetes·Li Zhang, George S Eisenbarth
May 7, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Linda AkermanRosaura Casas
Nov 15, 2007·Diabetes Care·Jay M SosenkoUNKNOWN Diabetes Prevention Trial-Type 1 Study Group
Jun 4, 2016·Journal of Autoimmunity·Andrea K SteckMarian J Rewers
Jan 5, 2018·The Journal of Clinical Endocrinology and Metabolism·Maarit K KoskinenRiitta Veijola
Jan 21, 2011·Physiological Reviews·Tom L van BelleMatthias G von Herrath
Jun 3, 2009·Diabetes Care·Jay M SosenkoUNKNOWN Diabetes Prevention Trial-Type 1 Study Group
Nov 21, 2017·Biomedicine Hub·Richard InselJoseph Hedrick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Related Papers

Best Practice & Research. Clinical Endocrinology & Metabolism
P Achenbach, A G Ziegler
Current Diabetes Reports
P AchenbachA G Ziegler
The New England Journal of Medicine
Diabetes Prevention Trial--Type 1 Diabetes Study Group
© 2021 Meta ULC. All rights reserved